跳至主要内容
临床试验/NCT07394036
NCT07394036尚未招募2 期

The Effect of Ipratropium Bromide on Exercise-Induced Laryngeal Obstruction (EILO) in Pediatric Patients

Cook Children's Health Care System1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2026年6月1日最近更新:
干预措施

试验速览

阶段
2 期
状态
尚未招募
入组人数
50
试验地点
1
主要终点
Visual Analogue Scale for Dyspnea (VAS-Dyspnea)

研究概览

简要总结

The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with Exercise-Induced Laryngeal Obstruction after breathing in ipratropium bromide or placebo. It is hypothesized that breathlessness and airway obstruction will be lower following breathing in ipratropium bromide compared with placebo.

详细描述

Many children and adolescents struggle with breathing problems during exercise. These symptoms can lead them to underperform, quit sports, and in some cases, stop being active altogether. One under-recognized cause is Exercise-Induced Laryngeal Obstruction (EILO), a narrowing of the airway at the level of the voice box. Approximately 5-8% of adolescents and 20-40% of adolescent athletes have EILO, an estimated 4-6 million nationwide. The most common treatment for EILO is Speech Therapy, with or without Physical Therapy. Where available, this requires significant time and financial commitment from patients and their families to attend therapy sessions and complete at-home exercises.

Case reports as early as 1985 have suggested aerosolized ipratropium bromide as an effective EILO treatment. One larger study could not confirm this observation. However, this study used an outcome measure with low reliability and validity, did not use a placebo control, and administered a low dose of ipratropium bromide too close to exercise.

The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with EILO following inhalation of a higher dose of nebulized ipratropium bromide with placebo. It is hypothesized that breathlessness and airway obstruction will be lower following inhalation of ipratropium bromide compared with placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
8 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients must be diagnosed with EILO confirmed by Continuous Laryngoscopy During Exercise
  • Patients must be able to complete exercise testing
  • Patients must report dyspnea
  • Patients must have given assent with parental consent, understand all study procedures, and comply with them for the entire length of the study.

排除标准

  • Patients that do not have EILO.
  • Patients who did not undergo diagnostic CPET with CLE.
  • Patients with hypersensitivity to atropine or its derivatives due to structural similarity with ipratropium bromide.
  • Patients with a history of atrial flutter and/or fibrillation
  • Patients taking anticholinergic medications that cannot be paused for 24 hours.
  • Unable to perform exercise tests
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of patient or parent/legally authorized representative to give written informed consent.

研究组 & 干预措施

Ipratropium Bromide, then Placebo

Experimental

Participants will receive Ipratropium Bromide in their first trial and Placebo in the second trial.

干预措施: Normal Saline (Placebo) (Drug)

Placebo, then Ipratropium Bromide

Experimental

Participants will receive Placebo in their first trial and Ipratropium Bromide in the second trial.

干预措施: Normal Saline (Placebo) (Drug)

Ipratropium Bromide, then Placebo

Experimental

Participants will receive Ipratropium Bromide in their first trial and Placebo in the second trial.

干预措施: Ipratropium Bromide (Drug)

Placebo, then Ipratropium Bromide

Experimental

Participants will receive Placebo in their first trial and Ipratropium Bromide in the second trial.

干预措施: Ipratropium Bromide (Drug)

结局指标

主要结局

Visual Analogue Scale for Dyspnea (VAS-Dyspnea)

时间窗: Day1 and Day 2

Shortness of breath assessed by a 0-100 Visual Analogue Scale for Dyspnea, where higher scores reflect greater breathlessness

次要结局

  • CLE grade scoring(Day 1 and Day 2)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验